Primary dysbetalipoproteinemia

Primary dysbetalipoproteinemia, also known as type III hyperlipoproteinemia or familial dysbetalipoproteinemia, is a rare inherited metabolic disorder of lipid clearance affecting the cardiovascular and integumentary systems It is primarily caused by homozygosity for the apolipoprotein E2 allele or other mutations in the *APOE* gene, which disrupt the binding of apolipoprotein E to hepatic receptors and impair the clearance of chylomicron and very-low-density lipoprotein remnants Clinically, aff...

Primary dysbetalipoproteinemia, also known as type III hyperlipoproteinemia or familial dysbetalipoproteinemia, is a rare inherited metabolic disorder of lipid clearance affecting the cardiovascular and integumentary systems

Primary dysbetalipoproteinemia, also known as type III hyperlipoproteinemia or familial dysbetalipoproteinemia, is a rare inherited metabolic disorder of lipid clearance affecting the cardiovascular and integumentary systems

It is primarily caused by homozygosity for the apolipoprotein E2 allele or other mutations in the *APOE* gene, which disrupt the binding of apolipoprotein E to hepatic receptors and impair the clearance of chylomicron and very-low-density lipoprotein remnants

It is primarily caused by homozygosity for the apolipoprotein E2 allele or other mutations in the *APOE* gene, which disrupt the binding of apolipoprotein E to hepatic receptors and impair the clearance of chylomicron and very-low-density lipoprotein remnants This defect results in mixed hyperlipidemia with roughly equimolar elevations in plasma cholesterol and triglycerides due to the accumulation of atherogenic remnant lipoproteins (beta-VLDL)

It is primarily caused by homozygosity for the apolipoprotein E2 allele or other mutations in the *APOE* gene, which disrupt the binding of apolipoprotein E to hepatic receptors and impair the clearance of chylomicron and very-low-density lipoprotein remnants This defect results in mixed hyperlipidemia with roughly equimolar elevations in plasma cholesterol and triglycerides due to the accumulation of atherogenic remnant lipoproteins (beta-VLDL) Clinically, affected individuals are at substantia...

This defect results in mixed hyperlipidemia with roughly equimolar elevations in plasma cholesterol and triglycerides due to the accumulation of atherogenic remnant lipoproteins (beta-VLDL)